0001104659-23-069912.txt : 20230609
0001104659-23-069912.hdr.sgml : 20230609
20230609161206
ACCESSION NUMBER: 0001104659-23-069912
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230607
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fernandes Peter
CENTRAL INDEX KEY: 0001642618
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36845
FILM NUMBER: 231005384
MAIL ADDRESS:
STREET 1: PERRYVILLE III CORPORATE PARK
STREET 2: 53 FRONTAGE ROAD, SUITE 301
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bellerophon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001600132
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473116175
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302
CITY: WARREN
STATE: NJ
ZIP: 07059
BUSINESS PHONE: 908-574-4770
MAIL ADDRESS:
STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302
CITY: WARREN
STATE: NJ
ZIP: 07059
FORMER COMPANY:
FORMER CONFORMED NAME: Bellerophon Therapeutics LLC
DATE OF NAME CHANGE: 20140213
4
1
tm2318251-8_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-07
0
0001600132
Bellerophon Therapeutics, Inc.
BLPH
0001642618
Fernandes Peter
20 INDEPENDENCE BLVD.
SUITE 402
WARREN
NJ
07059
0
1
0
0
See Remarks
0
Stock Options (Right to Buy)
0.8264
2023-06-07
4
A
0
100000
0
D
2033-06-07
Common Stock
100000
100000
D
This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023.
This option vests in 16 quarterly installments commencing on the date hereof.
Chief Executive Officer, Principal Financial and Accounting Officer
/s/ Peter Fernandes
2023-06-09